BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. (Q53189566)

12 May 2018

title

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. (English)

1 reference

12 May 2018

author

Martin Köbel

3

1 reference

12 May 2018

Brad H Nelson

Brad H Nelson

4

0 references

Jiarui Ding

9

Jiarui Ding

1 reference

12 May 2018

Katy Milne

8

Katy Milne

1 reference

12 May 2018

C. Blake Gilks

12

C Blake Gilks

1 reference

12 May 2018

Steve E Kalloger

6

Steve E Kalloger

1 reference

12 May 2018

Sohrab P. Shah

10

Sohrab P Shah

1 reference

12 May 2018

Jessica N McAlpine

1

Jessica N McAlpine

1 reference

12 May 2018

David Huntsman

11

David G Huntsman

1 reference

12 May 2018

author name string

Henry Porter

2

1 reference

12 May 2018

Leah M Prentice

5

1 reference

12 May 2018

Janine Senz

7

1 reference

12 May 2018

publication date

27 January 2012

1 reference

12 May 2018

published in

Modern Pathology

1 reference

12 May 2018

volume

25

1 reference

12 May 2018

issue

5

1 reference

12 May 2018

page(s)

740-750

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.211

exact match

0 references

cites work

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Identification of prognostic factors in advanced epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Prognostic factors in malignant epithelial ovarian tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

The impact of T-cell immunity on ovarian cancer outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

The relationship between the roles of BRCA genes in DNA repair and cancer predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

DNA double strand break repair in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Therapeutic exploitation of tumor cell defects in homologous recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Using specific cytotoxics with a targeted mind.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Improved survival in women with BRCA-associated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Fast and accurate short read alignment with Burrows-Wheeler transform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

The Sequence Alignment/Map format and SAMtools

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

The genesis and evolution of high-grade serous ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Dramatic Response to Platinum in a Patient with Cancer with a Germline BRCA2 Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Inactivation of BRCA1 and BRCA2 in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Frequency of BRCA1 dysfunction in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

Are all pelvic (nonuterine) serous carcinomas of tubal origin?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.211

7 January 2021

10.1038/MODPATHOL.2011.211

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

22282309

1 reference

12 May 2018